APM
RLMD icon

Avidity Partners Management’s Relmada Therapeutics RLMD Stock Holding History

Avidity Partners Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-731,536
Closed -$16.5M – 104
2021
Q4 		$16.5M Buy
+731,536
New +$16.3M 0.35% 58
2020
Q1 		– Sell
-10,000
Closed -$390K – 63
2019
Q4 		$390K Buy
+10,000
New +$304K 0.25% 33

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Avidity Partners Management's RLMD Position: Q1 2022 in Review

Avidity Partners Management sold out of Relmada Therapeutics (RLMD) in Q1 2022, closing a stake of 731,536 shares — an estimated $16.5M sold.

Avidity Partners Management first reported a position in RLMD in Q4 2019 and held it in 2 quarters. The position peaked at $16.5M in Q4 2021. 113 funds tracked by Wall St. Rank hold RLMD as of Q1 2022.

  • Avidity Partners Management reported no remaining Relmada Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Avidity Partners Management sold 731,536 Relmada Therapeutics shares in Q1 2022, an estimated $16.5M.
  • Avidity Partners Management first reported a position in Relmada Therapeutics in Q4 2019 and held it in 2 quarters.
  • Avidity Partners Management's Relmada Therapeutics position peaked at $16.5M in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2022.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.